Literature DB >> 3744386

Mechanisms of tumor growth inhibition.

Z Steplewski, D Herlyn, M Lubeck, Y Kimoto, M Herlyn, H Koprowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3744386

Source DB:  PubMed          Journal:  Hybridoma        ISSN： 0272-457X


× No keyword cloud information.
  8 in total

1.  The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma.

Authors:  H Mellstedt; J E Frödin; P Ragnhammar; G Masucci; J Shetye; B Christensson; P Biberfeld; J Makower; P Pihlstedt; B Cedermark
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 2.  Antibodies: At The Nexus of Antigens and Cancer Vaccines.

Authors:  Zenon Steplewski; Magdalena Thurin; Thomas Kieber-Emmons
Journal:  J Infect Dis       Date:  2015-07-15       Impact factor: 5.226

3.  Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

Authors:  J Shetye; J E Frödin; B Christensson; C Grant; B Jacobsson; S Sundelius; M Sylvén; P Biberfeld; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  G Masucci; P Wersäll; P Ragnhammar; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.

Authors:  P Ragnhammar; J E Frödin; P P Trotta; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

Review 6.  Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.

Authors:  A P Zbar; N R Lemoine; M Wadhwa; H Thomas; D Snary; W A Kmiot
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  Interleukin 1 and tumour necrosis factor alpha may be responsible for the lytic mechanism during anti-tumour antibody-dependent cell-mediated cytotoxicity.

Authors:  A M Pullyblank; P J Guillou; J R Monson
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

8.  m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer.

Authors:  A M Pullyblank; P J Guillou; J R Monson
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.